Breidahl H D, Topliss D J, Pike J W
Br Med J (Clin Res Ed). 1983 Aug 13;287(6390):451-2. doi: 10.1136/bmj.287.6390.451.
A patient with a macroprolactinoma was treated with bromocriptine 15 mg daily. Both the size of the tumour as shown by computed tomography and the serum prolactin concentration decreased over several months but then increased. The dose of bromocriptine was increased to 40 mg daily but tumour growth continued, and the tumour was resected. Production of prolactin by cultured cells was not inhibited by high concentrations of bromocriptine, suggesting that regrowth of the tumour was due to cells resistant to dopamine agonist action. This case of regrowth of a prolactinoma during bromocriptine treatment after an initial reduction in size indicates the need for close surveillance especially of patients whose serum prolactin concentration fails to fall into the normal range with bromocriptine treatment.
一名患有大泌乳素瘤的患者接受了每日15毫克溴隐亭的治疗。通过计算机断层扫描显示的肿瘤大小以及血清泌乳素浓度在几个月内均有所下降,但随后又升高了。溴隐亭剂量增加至每日40毫克,但肿瘤仍继续生长,于是进行了肿瘤切除。高浓度溴隐亭并未抑制培养细胞产生泌乳素,这表明肿瘤的再生长是由于对多巴胺激动剂作用有抗性的细胞所致。这个泌乳素瘤在最初体积缩小后溴隐亭治疗期间出现再生长的病例表明,尤其对于那些经溴隐亭治疗后血清泌乳素浓度未能降至正常范围的患者,需要进行密切监测。